Bavarian Nordic seeks EMA nod for Mpox vaccine in children aged 2–11

The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN

ENHERTU approved in China as first HER2-targeted ADC for early breast cancer

The decision is based on the phase 3 DESTINY-Breast11 trial

Wockhardt’s breakthrough antibiotic Zaynich wins key regulatory nod in India

Granules Life Sciences receives VAI Classification for Shamirpet facility

The inspection is now closed, and no regulatory action has been recommended

Rocket Pharma gets FDA nod for first pediatric gene therapy targeting severe LAD-I

The approval covers pediatric patients without a matched sibling donor for stem cell transplant

Philips launches game-changing interventional platform for cardiology

IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision

AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit

Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims

AstraZeneca’s breakthrough COPD drug Tozorakimab slashes flare-ups in landmark Phase III trials

High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo

Merck strikes $6.7 billion deal to acquire terns, bolstering cancer pipeline

TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances

Zealand Pharma launches major US research hub in Cambridge, Massachusetts

The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities